Thomas Seyfried Ph.D.
The world's leading metabolic cancer researcher with over 28 years experience.
Thomas Seyfried Ph.D., Professor of Biology at the prestigious Boston College, is undoubtedly the leading modern day cancer researcher. He is highly respected with decades of experience in the research arena, the lab and in the field. He is working with clinicians, assisting them to fully understand that cancer is a “metabolic” disease caused by damaged mitochondria, and how to implement his amazing “Press – Pulse” cancer therapy, based on the metabolic approach. Seyfried has also written the most advanced book on “metabolic cancer” which is quite technical and mainly for practitioners and therapists, based on his many years of research, called: “Cancer a Metabolic Disease” – On the Origin, Management and Prevention of Cancer.
I recommend that if you are not up to speed with medical jargon and the internal workings of the body, you should make time to watch some of Dr Seyfried’s video’s.
Dr Seyfried has been researching “cancer as a metabolic disease” for 28 years and has published over 180 peer reviewed research papers, conducted hundreds of lab trials and case studies as well as helping both Turkey and Egypt to establish a "Metabolic Cancer" clinic practicing Dr Seyfried’s treatment protocols with unbelievable success. Especially for brain cancer. Glioblastoma is one of the most aggressive brain cancers with very few 5 year survivors using conventional "Standard of Care' cancer treatments.
Through his extensive and comprehensive research he has categorically established that cancer is a “metabolic mitochondrial disease", and he has also managed to find the time to share this information and spread the word and present his findings.
Hopefully over the next few years the public do become fully aware and understand this enormous breakthrough in cancer treatment. This will eliminate the dogma that cancer is a “genetic disease” and hopefully over the next few years the “metabolic” approach will take over the “standard of care” cancer treatment as we know it today.
I share the following 2 remarks Dr Seyfried recently made:
"A dogma is considered irrefutable truth, and that cancer is a genetic disease is, no question, a dogma. The problem with dogma is that sometimes it blinds you to alternative views and sets up ideologies that are extremely difficult to change.
In my view, this information is the game changer that not only treats cancer but virtually every single disease known to man, because at the core of most serious ailments you find mitochondrial dysfunction. As noted by Seyfried:
Emerging evidence indicates that cancer is primarily a metabolic disease involving disturbances in energy production through respiration and fermentation.
Cancer is suppressed following transfer of the nucleus from the tumor cell to cytoplasm of normal cells containing normal mitochondria. These findings indicate that nuclear genetic abnormalities cannot be responsible for cancer despite commonly held beliefs in the cancer field. The genomic instability observed in tumor cells and all other recognized hallmarks of cancer are considered downstream epiphenomena of the initial disturbance of cellular energy metabolism. The disturbances in tumor cell energy metabolism can be linked to abnormalities in the structure and function of the mitochondria. Cancer growth and progression can be managed following a whole-body transition from fermentable metabolites, primarily glucose and glutamine, to respiratory metabolites, primarily ketone bodies. This transition will reduce tumor vascularity and inflammation while enhancing tumor cell death. A novel “press-pulse” therapeutic strategy is in development for the non-toxic metabolic management of cancer. Malignant brain cancer in preclinical models and humans will be used to illustrate general concepts. As each individual is a unique metabolic entity, personalization of metabolic therapy as a broad-based cancer treatment strategy will require fine-tuning to match the therapy to an individual’s unique physiology.
Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations.
He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology.
Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.
Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.
Dr. Seyfried has over 180 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).”